ANCA-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function due to necrotizing glomerulonephritis. Tune in to find out how to incorporate targeted therapies when managing AAV. Your patients will thank you for joining our experts, Drs. Bernhard Hellmich and David Jayne, in their discussion.
Incorporating Targeted Therapies in Treatment Planning for AAV
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
David Jayne, MD
Professor of Clinical Autoimmunity
Department of Medicine
University of Cambridge
Cambridge, United KingdomConsulting Fees: Amgen, AstraZeneca, Bristol Myers Squibb, CSL Vifor, GSK, Novartis, Roche, Takeda
Contracted Research: GSK, Roche
Ownership Interest: AuriniaFaculty:
Bernhard Hellmich, MD
Chair, Department of Medicine
Medius Kliniken, University of Tübingen
Baden-Württemberg, GermanyConsulting Fees: AbbVie, Astra Zeneca, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, Novartis
Royalties: AbbVie, Amgen, BMS, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, MSD, Novartis, Pfizer, Phadia, RocheReviewers/Content Planners/Authors:
- Megan Clem has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Howard Green has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Tim Person has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the role of the alternative complement pathway in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
- Contrast efficacy and safety of induction and maintenance therapies in managing patients with ANCA-associated vasculitis
- Identify patients who may benefit from C5a receptor inhibitors
Target Audience
This activity is designed to meet the educational needs of nephrologists and rheumatologists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
0.25 creditsDavid Wheeler, MB, CHB, MD, FRCP
Stephen McAdoo, MD
Khalil El Karoui, MD
Federico Alberici, MD, PhD
Joel Topf, MD
James Burton, MD